Sugi Predict

Sugi Predict / Compounds / SCHEMBL4273522

SCHEMBL4273522

SCHEMBL4273522

Cc1ccc(C(F)(F)F)c(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ SYK P43405 1/20 0.43
▸ AR P10275 6/20 0.41
▸ CYP11B1 P15538 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ KIF11 P52732 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2A6 P11509 2/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.38
▸ NOTUM Q6P988 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36
▸ RXRG P48443 1/20 0.36
▸ ACHE P22303 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19267570 0.88 SMN1; SMN2 (0.41) SMN1; SMN2SYKARCYP11B1CYP11B2
SCHEMBL12773798 0.88 SMN1; SMN2 (0.43) SMN1; SMN2SYKARCYP11B1CYP11B2
SCHEMBL6371416 0.88 SMN1; SMN2 (0.43) SMN1; SMN2SYKARCYP11B1CYP11B2
SCHEMBL19267576 0.88 SMN1; SMN2 (0.41) SMN1; SMN2SYKARCYP11B1CYP11B2
SCHEMBL144686 0.82 TP53 (0.42) SMN1; SMN2SYKARCYP11B1CYP11B2
SCHEMBL84053 0.82 SMN1; SMN2 (0.44) SMN1; SMN2SYKARKIF11CYP1A2
SCHEMBL10030392 0.82 GLA (0.54) SMN1; SMN2SYKARKIF11CYP1A2
SCHEMBL22140197 0.81 SMN1; SMN2 (0.37) SMN1; SMN2SYKARCYP11B1CYP11B2
SCHEMBL764426 0.80 CYP11B2 (0.53) CYP11B1CYP11B2KIF11
SCHEMBL168982 0.80 MPL (0.44) SMN1; SMN2SYKARCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210280795-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Beijing Summer Sprout Technology Co., Ltd. (CN) 2021-09-09 — — US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed
US-20200235304-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2020-07-23 — — US disclosed
EP-2925747-B1 AZAQUINAZOLINE CARBOXAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-24 — — EP disclosed
WO-2019078620-A1 NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME 주식회사 엘지화학 2019-04-25 — — WO disclosed
WO-2019005841-A1 THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-01-03 — — WO disclosed
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 — — US disclosed
US-9771359-B1 Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II MEDIFRON DBT INC. (KR) 2017-09-26 — — US disclosed
US-20170253586-A1 Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II MEDIFRON DBT INC. (KR) 2017-09-07 — — US disclosed
US-9744186-B2 Substituted gemcitabine aryl amide analogs NUCORION PHARMACEUTICALS, INC. (US) 2017-08-29 — — US disclosed
US-7355053-B2 1-phenylpyrrolidine-2-one-3-carboxamides BASF AKTIENGESELLSCHAFT (DE) 2008-04-08 — — US disclosed
WO-2007147701-A1 AZOLINE COMPOUNDS FOR COMBATING ARTHROPOD PESTS BASF SE (DE) 2007-12-27 — — WO disclosed
US-6737429-B2 TREATMENT OF HIV MEDIATED DISEASES. HOFFMANN-LA ROCHE INC. 2004-05-18 — — US disclosed
EP-1417202-A2 AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-05-12 — — EP disclosed
EP-1301481-A1 PYRROLE DERIVATIVES FOR TREATING AIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-16 — — EP disclosed
US-20030069276-A1 Amino piperidine derivatives F.HOFFMANN-LA ROCHE AG (CH) 2003-04-10 — — US disclosed
WO-2002079186-A2 AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2002-10-10 — — WO disclosed
US-20020032221-A1 Pyrrole derivatives ROCHE PRODUCTS LIMITED (GB) 2002-03-14 — — US disclosed
WO-2002002524-A1 PYRROLE DERIVATIVES FOR TREATING AIDS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-10 — — WO disclosed
US-4208430-A CARBAMIMIDOTHIOIC ACID PHENYLALKYL ESTERS SMITHKLINE CORPORATION (US) 1980-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210280795-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SLC18A2, SLC43A1, SLC18A1 SMN1; SMN2 3470/4885SYK 3978/4885AR 1781/4885
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 SMN1; SMN2 250/4885SYK 3297/4885AR 4220/4885
US-20030069276-A1 Amino piperidine derivatives CCR5, CCR2, CXCR4 SMN1; SMN2 4829/4885SYK 4349/4885AR 2843/4885
US-20020032221-A1 Pyrrole derivatives PYCR1, SARS1, MAVS SMN1; SMN2 2911/4885SYK 2026/4885AR 4413/4885
US-20170253586-A1 Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II TRPV1, TRPV2, GPR17 SMN1; SMN2 2966/4885SYK 1570/4885AR 794/4885
US-20200235304-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME C1S, CBR3, CCNL2 SMN1; SMN2 3242/4885SYK 4533/4885AR 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.